Siili Solutions Oyj
Siili Solutions Plc: Share Repurchase 25.6.2025
Siili Solutions Plc: Share Repurchase 25.6.2025
Siili Solutions Plc | Announcement 25.6.2025 | |
Siili Solutions Plc: Share Repurchase 25.6.2025 | ||
In the Helsinki Stock Exchange | ||
Trade date | 25.6.2025 | |
Bourse trade | Buy | |
Share | SIILI | |
Amount | 600 | Shares |
Average price/ share | 6,3400 | EUR |
Total cost | 3 804,00 | EUR |
Siili Solutions Plc now holds a total of 17 749 shares | ||
including the shares repurchased on 25.6.2025 | ||
The share buybacks are executed in compliance with Regulation | ||
No. 596/2014 of the European Parliament and Council (MAR) Article 5 | ||
and the Commission Delegated Regulation (EU) 2016/1052. | ||
On behalf of Siili Solutions Plc | ||
Nordea Bank Oyj | ||
Sami Huttunen | Ilari Isomäki | |
Further information: | ||
CFO Aleksi Kankainen | ||
Email: aleksi.kankainen@siili.com | ||
Tel. +358 50 584 2029 | ||
www.siili.com | ||
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Alvotech25.6.2025 22:45:00 CEST | Press release
Main Results of 2025 Annual and Extraordinary General Meeting
Teva Pharmaceutical Industries Ltd25.6.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
Golar LNG25.6.2025 22:15:07 CEST | Press release
Golar LNG Limited Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2030
DBV Technologies S.A.25.6.2025 22:15:00 CEST | Press release
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Idorsia Pharmaceuticals Ltd25.6.2025 19:15:00 CEST | Press release
Bondholders approve amended terms of the 2025 and 2028 convertible bonds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom